![](/img/cover-not-exists.png)
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout
Michael A. Becker, H. Ralph Schumacher Jr., Robert L. Wortmann, Patricia A. MacDonald, William A. Palo, Denise Eustace, Laurent Vernillet, Nancy Joseph-RidgeVolume:
52
Year:
2005
Language:
english
Pages:
8
DOI:
10.1002/art.20935
File:
PDF, 168 KB
english, 2005